Status:

UNKNOWN

Magnesium Sulphate to Bupivicaine in Serratus Anterior Plane Block in Modified Radical Mastectomy

Lead Sponsor:

Alexandria University

Conditions:

Cancer Breast

Chronic Pain Syndrome

Eligibility:

FEMALE

20-70 years

Phase:

PHASE2

PHASE3

Brief Summary

Modified radical mastectomy may be associated with severe post-operative pain, leading to chronic pain syndrome which usually requires optimal perioperative pain management.

Detailed Description

Patients will be randomly into two equal groups (40 patients each) according to the adjuvant added to the local anesthetic (bupivacaine) in the serratus anterior plane block using a computer-generated...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • adult female patients
  • American Society Of Anesthesiologists (ASA) class I or II
  • scheduled for elective unilateral modified radical mastectomy
  • Exclusion Criteria
  • patient refusal
  • bilateral breast surgery
  • coagulation disorders
  • body mass index\> 35
  • allergy to local anaesthetics or magnesium sulphate
  • severe respiratory or cardiac disorders
  • pre-existing neurological deficits
  • liver or renal insufficiency

Exclusion

    Key Trial Info

    Start Date :

    January 1 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    September 1 2022

    Estimated Enrollment :

    80 Patients enrolled

    Trial Details

    Trial ID

    NCT04429893

    Start Date

    January 1 2022

    End Date

    September 1 2022

    Last Update

    August 2 2022

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Rehab Abd Elraof Abd Elaziz

    Alexandria, Smouha, Egypt, 000000

    Magnesium Sulphate to Bupivicaine in Serratus Anterior Plane Block in Modified Radical Mastectomy | DecenTrialz